Session 13: Breaking News
Dr Frédéric DOLLE
CEA, SERVICE HOSPITALIER FRÉDÉRIC JOLIOT, Orsay, France
Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety
Dr Claire BOUIX-PETER
GALDERMA R&D, Sophia-Antipolis, France
Claire Bouix-Peter, Ph.D. is head of Medicinal Chemistry at Galderma (Sophia Antipolis, France). Her research field focus mainly on topical administration to treat dermatological diseases. Experience in targeting enzymes, GPCR, Nuclear Receptors for dermatological indications like acne, steroid responsive disorders and pigmentary disorders.
Education and past experience: Sanofi-Aventis : (2000-2001) : Chemist in Medicinal Chemistry ; Postdoctoral Research Fellow with Prof. B Trost, University of Stanford, U.S.A. (1999-2000) - Molybdenum-Catalyzed Asymmetric Allylic Alkylation - Ph.D. in Organic Chemistry with Prof. J. Eustache, Université de Haute Alsace (Mulhouse), France (1996-1999) - Stereoselective synthesis of arabinose-derived phosphonates
SOM230: A New Therapeutic Modality for Cushing’s Disease
Dr Ian LEWIS
NOVARTIS, Basel, Switzerland
Ian Lewis studied chemistry at the University of Edinburgh between 1981 – 1985 and then carried out a Ph.D. at the University of Edinburgh between 1985 – 1988 under the supervision of Professor R. Ramage on the synthesis of polyene teramic acid antibiotics. Subsequently Ian Lewis carried out a Royal Society Post-doctoral Fellowship at ETH Zürich between 1988 – 1990 in the research group of Professor A. Eschenmoser and then joined Novartis (originally Sandoz) in 1990, researching in the endocrinology and immune disease areas. Between 2001 – 2002 Ian Lewis was a Novartis Guest Scientist at the Scripps Research Institute, La Jolla, in the group of Professor K. Barry Sharpless, during the time Professor Sharpless was awarded the Nobel Prize in Chemistry. Since then Ian has carried out research in the Exploratory Medicinal Chemistry Unit of the Oncology Global Discovery Chemistry Organisation.
Coffee Break, Poster Session and Exhibition
Session 14: Antibody Drug Conjugates
Sponsored by Pierre Fabre Research Institute
Dr Alain BECK
PIERRE FABRE, St Julien-en-Genevois, France
Dr. A. Beck is Director of Antibody Physico-Chemistry and member of the board of directors of the Centre d’Immunologie Pierre Fabre (CIPF). He contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11/cMet with Abbott, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides. He is inventor on 16 patents, author of 80 publications, associate editor of mAbs (www.landesbioscience.com) and guest editor for special issues on mAbs (Nat Rev Immunol, Curr Pharm Biotech, Medecine/ Sciences and Meth Mol Biol). He has contributed to 130 scientific meetings as chairman, invited speaker, panelist, moderator, advisor, and/or organizer. He is also regularly invited to boards of experts by the WHO, the EMA, the European Commission, Funding Agencies (Czech, Dutch, France, Ontario, New Zealand) and bio-clusters (Alsace Biovalley, CLARA, Genopole, LyonBiopole).
Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy
Dr Ravi CHARI
IMMUNOGEN, Waltham, United States
Ravi Chari is Executive Director of Chemistry & Biochemistry at ImmunoGen, Inc., a biopharmaceutical company located in Waltham, MA. His group is responsible for the development of potent cytotoxic compounds for tumor-specific delivery in the form of antibody-drug conjugates (ADCs). His group also designs novel linkers to generate ADCs with optimal anti-tumor activity. Dr. Chari received his doctorate in Chemistry from the University of Detroit, Detroit, MI. Subsequently, he was a postdoctoral fellow in the Pharmacology department at the Yale University – School of Medicine, where he was in involved in the design and synthesis of mechanism-based enzyme inhibitors. In 1986, he joined the Dana-Farber Cancer Institute/Harvard Medical School as a research scientist, where he initiated work on the use of monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells.
Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics
Dr Jagath Reddy JUNUTULA
GENENTECH, South San Francisco, United States
Jagath Junutula is Senior Scientist, Genentech Research and Development (gRED), Genentech, Inc. He joined Genentech, Inc. in 2001 and is currently a Senior Scientist in the Research and Early Development Division (gRED). He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. Jagath has over 10 years of experience in oncology drug discovery and development and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Jagath gained knowledge and experience in moving antibody-based therapeutic molecules from discovery phase to IND. He has authored 50 peer-reviewed publications/patents and has presented his work at numerous international conferences. He received the INSA (Indian National Science Academy) Young Scientist Award for outstanding graduate research work, and the Shamrao Kaikini medal for the best PhD thesis in Biological and Chemical Sciences from the Indian Institute of Science. He is a member of the American Society for Cell Biology and the American Association for Cancer Research. He served as a President (2010-2011) of EPPIC, a non-profit organization that fosters entrepreneurial mentoring, partnering and networking among Pharma/Biotech professionals and has been a board member since 2010.
Session 15: European Lead Factory
Sponsored by ELF Chemistry SMEs : Edelris, Mercachem, Sygnature, Syncom, Taros
Prof. Joachim MITTENDORF
BAYER PHARMA AG, Wuppertal, Germany
The European Lead Factory - A Novel Discovery Partnership Model
Dr Jörg HUESER
BAYER PHARMA, Wupperthal, Germany
Jörg Hüser studied Biology at Ruhr-University Bochum (Germany). He received a Ph.D. in cellular physiology studying cardiac electro-mechanical coupling. After a four year postdoctoral training in the Department of Physiology, Loyola University Chicago, Maywood, IL, USA, he joined Bayer Pharma Research in Wuppertal, Germany, as a Scientist in the Institute of Molecular Screening Technology. Today, Jörg Hüser is heading this function, now called Lead Discovery Wuppertal.
In addition, Jörg Hüser is the coordinator of a recently launched Innovative Medicine Initiative project called “European Lead Factory”.
Lunch, Poster Session and Exhibition
Session 16: Case Studies, Pain & Cancer
Dr Henning STEINHAGEN
GRÜNENTHAL, Verona, Italy
DAAO Inhibitors as Clinical Candidates
Dr Michele HEFFERNAN
SUNOVION PHARMACEUTICALS, Marlborough, United States
Michele Heffernan is a medicinal chemistry project leader at Sunovion Pharmaceuticals (formerly Sepracor) in Marlborough, MA, USA. Michele obtained her Ph.D. in organic chemistry from Boston College in 1998 under the supervision of Professor Marc Snapper. She then joined Sepracor, and has worked in area of CNS Drug Discovery for the past 15 years, leading a number of projects from hit ID through lead optimization to Advanced Lead nomination. She has experience leading projects with a range of target classes including enzymes, GPCRs, and ion channels.
How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway
Dr Eric LINGUEGLIA
CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France
Eric Lingueglia, 46, is Director of Research at INSERM, and is studying ion channels for over 20 years. He completed his Ph.D. in the laboratory of Prof. Michel Lazdunski and worked for two years in the Department of Cell Biology of Harvard Medical School in Boston. Since 2007, he leads the "Ion Channels and Pain" team at the Institute of Molecular and Cellular Pharmacology of the CNRS - University of Nice Sophia Antipolis. His team studies the properties and the role of ion channels in pain by combining molecular and cellular biology, electrophysiology, pharmacology including the discovery and the use of peptides derived from animal venoms and specifically targeting these channels, and animal behaviour. Recently Dr. Lingueglia’s team has identified a new class of peptides from black mamba venom, which are able to inhibit particular subtypes of Acid-Sensing Ion Channels to produce a potent analgesia in mice comparable to morphine but independent of opiates.
Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers
Dr Frank HALLEY
SANOFI, Vitry-sur-Seine, France
Dr Frank Halley is Team Leader in Oncology Drug Discovery and Preclinical Development in Sanofi.
Research field :
22 years of experience in different therapeutic areas: cardiovascular (ACAT, angiotensin II, endothelin, PDGF and C5a), Respiratory/Inflammation (RANTES antagonists, prolyl-4-hydroxylase antagonists, VLA-4, CCR2, CCR3, CCR4 antagonists, p38 inhibitors, and cathepsin S inhibitors), anti-infective (Methionine Amino Peptidase and Secretases), oncology (angiogenesis KDR, Tie2, CDKs, IGF-1R,CDKs, HSP90, PI3K, MEK) and CNS (Alzheimer diseases, PDE4, PAK3, CK1).
Poster Prizes and Conclusive Remarks
Prof. Janos SAPI
SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France